Targeting the immune cells, tumor cells or even both, our technology is particularly well suited for immuno-oncology applications.

For example, our most advanced Proof-of-Concept led in collaboration with CNRS, Gustave Roussy Institute and Dijon Hospital (CGFL), illustrate a gain in immunization efficacy by targeting cDC1 and by delivering tumor antigens. Compared to conventional methods, this targeted approach is designed to activate robustely the immune system specifically against tumor cells, enabling their selective destruction.

An effective immunization platform is especially valuable for therapeutic cancer vaccines, aimed at eliminating residual cancer cells and reducing the risk of relapse. In many cancer indications, these residual cancer cells are poorly vascularized, making current immunotherapies and chemotherapies (iv injections) less effective. The consequence is often a cancer relapse that leads to another line of chemotherapy, then the death.